Edition:
India

Neovasc Inc (NVCN.OQ)

NVCN.OQ on NASDAQ Stock Exchange Capital Market

0.51USD
18 Apr 2019
Change (% chg)

$-0.03 (-5.56%)
Prev Close
$0.54
Open
$0.63
Day's High
$0.66
Day's Low
$0.50
Volume
3,069,002
Avg. Vol
348,171
52-wk High
$5.21
52-wk Low
$0.37

Latest Key Developments (Source: Significant Developments)

Neovasc Resolves Three Claims For Correction Of Patent Inventorship Made By Edwards Lifesciences CardiAQ LLC
Thursday, 18 Apr 2019 

April 17 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES RESOLUTION OF LAST REMAINING ACTIVE LITIGATION.NEOVASC - HAS RESOLVED THREE CLAIMS FOR CORRECTION OF PATENT INVENTORSHIP MADE BY EDWARDS LIFESCIENCES CARDIAQ LLC IN U.S. COURT.  Full Article

Neovasc Announces Pricing Of $5 Mln Public Offering Of Common Shares
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON SHARES.SAYS OFFERING OF 11.1 MILLION COMMON SHARES PRICED AT $0.45PER SHARE.  Full Article

Neovasc Announces Proposed Public Offering Of Common Shares
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.NEOVASC INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOVASC REDUCER, DEVELOPMENT OF TIARA.  Full Article

Neovasc Inc - On Feb 19, 2019, Company Entered Into A Settlement Agreement With MID
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Neovasc Inc ::NEOVASC PROVIDES CORPORATE UPDATE.NEOVASC INC - ON FEBRUARY 19, 2019, COMPANY ENTERED INTO A SETTLEMENT AGREEMENT WITH MID.NEOVASC INC - AGREEMENT RESOLVES CERTAIN POTENTIAL CLAIMS AGAINST COMPANY THAT WERE DESCRIBED IN ITS MANAGEMENT'S DISCUSSION AND ANALYSIS FOR Q3 2018.NEOVASC INC - SETTLEMENT AGREEMENT CONTEMPLATES CERTAIN FEES BEING PAID BY NEOVASC TO MID.NEOVASC INC - NEOVASC WILL PAY MID A ROYALTY OF 1.3% ON ANNUAL NET SALES OF TIARA.  Full Article

Neovasc Receives Approval To Proceed With Phase 2 Of Tiara-Ii Study
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Neovasc Inc ::NEOVASC RECEIVES APPROVAL TO PROCEED WITH PHASE 2 OF TIARA-II STUDY FROM CLINICAL REGULATORS IN GERMANY AND THE UK.NEOVASC - APPROVAL COMES FOLLOWING CLINICAL EVENTS COMMITTEE ADJUDICATION OF ADVERSE EVENTS, DATA AND SAFETY MONITORING BOARD REVIEW OF DATA, OTHER.NEOVASC - APPROVAL WILL ALLOW TIARA-II STUDY TO PROCEED IN THESE GEOGRAPHIES WITH NO RESTRICTIONS.  Full Article

Neovasc Announces Dismissal Of Claim Brought By Edwards Lifesciences
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES DISMISSAL OF CLAIM BROUGHT BY EDWARDS LIFESCIENCES.  Full Article

Neovasc Inc - QTRLY Loss Per Share $0.70
Thursday, 15 Nov 2018 

Neovasc Inc ::NEOVASC ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.NEOVASC INC - QTRLY LOSS PER SHARE $0.70.  Full Article

Neovasc Provides Initial Comments On Lawsuit
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - Neovasc Inc ::NEOVASC PROVIDES INITIAL COMMENTS ON LAWSUIT.NEOVASC INC - COMPLAINT HAS NOT YET BEEN SERVED ON COMPANY.NEOVASC INC - MADE AWARE OF A LAWSUIT FILED BY ENDOVALVE INC. AND MICRO INTERVENTIONAL DEVICES, INC.NEOVASC INC - IF PLAINTIFFS DO SERVE COMPLAINT, CO INTENDS TO DEFEND THE LAWSUIT.NEOVASC - FILED LAWSUIT FOR SOME ALLEGATIONS RELATING TO NEOVASC'S TRANSCATHETER MITRAL VALVE TECHNOLOGY, INCLUDING TIARA DEVICE.  Full Article

Capital World Investors Reports A 13.8 Percent Passive Stake In Neovasc Inc
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Neovasc Inc ::CAPITAL WORLD INVESTORS REPORTS A 13.8 PERCENT PASSIVE STAKE IN NEOVASC INC AS OF NOVEMBER 30, 2017 - SEC FILING.  Full Article

Neovasc announces 65 million dollars offering of common shares and warrants
Friday, 10 Nov 2017 

Nov 10 (Reuters) - NEOVASC INC ::NEOVASC ANNOUNCES US$65 MILLION UNDERWRITTEN OFFERING OF UNITS CONSISTING OF COMMON SHARES AND WARRANTS TO PURCHASE COMMON SHARES AND CONCURRENT PRIVATE PLACEMENT OF NOTES AND WARRANTS.‍PRICE OF US$1.46 PER UNIT FOR GROSS PROCEEDS OF APPROXIMATELY US$37.487 MILLION​.WILL ALSO COMPLETE BROKERED PRIVATE PLACEMENT FOR SALE OF US$32,750,000 AGGREGATE PRINCIPAL AMOUNT OF SENIOR SECURED CONVERTIBLE NOTES FOR GROSS PROCEEDS OF US$27,837,500​.‍ CANACCORD GENUITY INC. IS ACTING AS SOLE BOOK-RUNNING MANAGER FOR OFFERING​.‍CANACCORD GENUITY INC ACTS ALSO AS SOLE PLACEMENT AGENT FOR CONCURRENT PRIVATE PLACEMENT​.  Full Article